



**IBA Launches the New Dolphin™ Transmission Detector  
ONLINE Care. ONLINE Control. ONLINE Confidence.**

**Dolphin online treatment monitoring provides confidence and peace of mind knowing that your radiation therapy is safe and accurate until the last fraction.**

**San Francisco, September 16, 2014** – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the launch of the next evolution in patient safety, **Dolphin**. This announcement is made at the annual congress of the American Society of Radiation Oncology (ASTRO). **Dolphin** provides Online Care by enabling a more positive and safer treatment experience for the patients. **Dolphin's** friendly design supports the radiation therapist in comforting the patient for more compliant and accurate treatment delivery. It measures the actual delivery during the patient treatment, and the measured detector response is transmitted wirelessly to the **Dolphin** workstation at the treatment console.

Online Control is gained when **Dolphin** performs automatic and instant online treatment evaluation. The QuickCheck™ software automatically analyzes the delivered fraction vs. the treatment plan and automatically confirms its correctness immediately after each fraction, thus providing seamless integration into the therapist's workflow. If discrepancies occur, a notification message is displayed within seconds after the treatment. Verification results for "OK" and "Evaluate" can be set according to the clinic's individual thresholds. Notifications can be sent automatically via email for further evaluation. It can then be determined when re-planning or plan adaptation is required, or if machine specific tests are necessary. The clinical relevance of the dose discrepancies can be determined comprehensively with DVH and in 3D patient anatomy.

**Dolphin** provides Online Confidence that the entire treatment was delivered safely, fraction by fraction, until the last fraction. It provides confidence and peace of mind for patients knowing that **Dolphin** is safeguarding their entire treatment. And clinics can be confident that a new industry standard has been set to assure the correctness of each treatment.

*"Transmission Detector with COMPASS software offers an ultimate end-to-end test to independently verify any treatment technique (including complex treatments such as static IMRT/VMAT) and to visualize dosimetric outcome," says Dr. Frank Lohr, Department of Radiation Oncology, University of Heidelberg, Mannheim, Germany. "This unique QA tool does not require extra pretreatment QA-time, does not strain on EPIDs and will be usable for every deliverable field including all noncoplanar orientations up to the full deliverable field size on the largest collimators in clinical use (40 x 40 cm) currently not covered by EPID dosimetry."*

*"With the evolutionary technology of the **Dolphin** Transmission Detector, IBA is setting a new industry standard in patient safety QA by independently verifying the dose that is delivered to the patient while the patient is being treated," stated Rob Plompen, President of IBA Dosimetry. "Besides, **Dolphin's** patient-friendly design contributes to patients feeling more comfortable, relaxed and positive. We believe that the innovation that **Dolphin** offers both in terms of technology as well as design is a strong support to the mission of our customers in providing safe treatments and in achieving the best possible clinical outcomes."*



**About IBA**

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. IBA is the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centres as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety, as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the USA and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com).

**Media Contact:**

Suzanne Shankle  
IBA Dosimetry  
3150 Stage Post Drive  
Bartlett, TN 38133  
(901) 386-2242  
[Suzanne.shankle@iba-dosimetry.com](mailto:Suzanne.shankle@iba-dosimetry.com)  
[Suzanne.shankle@iba-group.com](mailto:Suzanne.shankle@iba-group.com)

<http://www.iba-dosimetry.com>

Press release | **September 16, 2014**

###